Reproductive effects of chronic administration of murine interferon- gamma

Reproductive Toxicology

Volumn 10, Issue 5, 1996, Pages 379-391

  Bussiere, Jeanine L ^a   Hardy, Laurel M ^b   Hoberman, Alan M ^b   Foss, John A ^b   Christian, Mildred S ^b  

^a GENENTECH INC   (United States)

^b NONE

Author keywords

bacterial infections; behavioral development; interferon gamma; male fertility; mice; postnatal development; reproductive toxicity; sexual maturation

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE;

EID: 0030250381     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/0890-6238(96)00084-6     Document Type: Article

References (78)

1. 1. Isaacs A, Lindenmann J. Virus interference. I. The interferons. Proc R Soc Lond B [Biol Sci] 1957;147:258-67.
2. 2. Kullberg B, van 't Wout J. Cytokines in the treatment of fungal infections. Biotherapy. 1994;7:195-210.
3. 3. Langermans J, van Furth R. Cytokines and the host defense against Listeria monocytogenes and Salmonella typhimurium. Biotherapy. 1994;7:169-78.
4. 4. Ho J, Badaro R, Hatzigeorgiou D, Reed S, Johnson WJ. Cytokines in the treatment of leishmaniasis: From studies of immunopathology to patient therapy. Biotherapy. 1994;7:223-35.
5. 5. Garner R. Kurucanti U, Czarniecki C, Chiu H, Domer J. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect Immun. 1989;57: 1800-8.
6. 6. Murray H. Interferon-gamma and host antimicrobial defense: Current and future clinical applications. Am J Med. 1994;97:459-67.
7. 7. Murray H. Interferon-gamma, the activated macrophage, and host defense against microbial challenge. Ann Intern Med. 1988;108: 595-608.
8. 8. Murray H. Gamma interferon, cytokine-induced macrophage activation, and antimicrobial host defense: In vitro, in animal models, and in humans. Diagn Microbiol Infect Dis. 1990;13:411-21.
9. 9. Dianzani F. Biological basis for the clinical use of interferon. Gut. 1993;Supplement:S74-S6.
10. 10. Champsi J, Bermudez L, Young L. The role of cytokines in mycobacterial infection. Biotherapy. 1994;7:187-93.
11. 11. Nathan C, Squires K, Griffo W, et al. Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon γ. J Exp Med. 1990;172:1509-12.
12. 12. Sundar S, Rosenkaimer F, Murray H. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-γ. J Infect Dis. 1994;170:659-62.
13. 13. Kruskal B, Ezekowitz R. Cytokines in the treatment of primary immunodeficiency. Biotherapy. 1994;7:249-59.
14. 14. Aulitzky W, Gastl G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol. 1989;7:1875-84.
15. 15. Key L Jr, Rodriguez R, Willi S. et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med. 1995;332:1594-9.
16. 16. Lemmel E, Brackertz D, Franke M, et al. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int. 1988;8:87-93.
17. 17. Ezekowitz R. Clinical efficacy of recombinant human interferongamma (rIFN-γ) in chronic granulomatous disease (CGD). Clin Res. 1990;38:465A.
18. 18. Todd PA, Goa KL. Interferon gamma-1b: A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs. 1992;43:111-22.
19. 19. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991; 324:509-16.
20. 20. Hussain M, Wozniak AJ, Edelstein MB. Neurotoxicity of antineo-plastic agents. Crit Rev Oncol/Hematol. 1993;14:61-75.
21. 21. Sriskandan K, Garner P, Watkinson J, et al. A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer. Cancer Chemother Pharmacol. 1986;18:63-8.
22. 22. Trown P, Wills R, Kamm J. The preclinical development of Roferon-A. Cancer. 1986;57:1648-56.
23. 23. Gray P, Goeddel D. Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci USA. 1983;80:5842-6.
24. 24. Green J, Terrell T. Utilization of homologous proteins to evaluate the safety of recombinant human proteins-case study: Recombinant human interferon-gamma (rhIFN-γ). Toxicol Lett. 1992;64/ 65:321-7.
25. 25. Shalaby M, Svedersky L, McKay P, Finkle B, Palladino MJ. In vivo augmentation of natural killer activity by combined treatment with recombinant gamma interferon and interleukin-2. J Interferon Res. 1985;5:571-81.
26. 26. Murray H, Spitalny G, Nathan C. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-γ. J Immunol. 1985; 134:1619-22.
27. 27. Kubelka C, Ruppel A, Gemsa D. Krammer P. In vivo activation of macrophages by T cell-derived lymphokines: Killing of tumor cells and schistosomula of Schistosoma mansoni. Immunobiol. 1986; 171:311-9.
28. 28. Black C, Catterall J, Remington J. In vivo and in vitro activation of alveolar macrophages by recombinant interferon-γ. J Immunol. 1987;138:491-5.
29. 29. Brummer E, Hanson L, Restrepo A, Stevens D. In vivo and in vitro activation of pulmonary macrophages by IFN-γ for enhanced killing of Paracoccidioides brasiliensis or Blastomyces dermatitidis. J Immunol. 1988;140:2786-9.
30. 30. Nomura M, Kakihata K, Ohno H, Fujii F. Onodera T. Simulation toxicity study of gene-recombinant-interferon gamma with mice. Toxicol Lett. 1986;31:44.
31. 31. Segall MA, Crnic LS. An animal model for the behavioral effects of interferon. Behav Neurosci. 1990;104:612-8.
32. 32. Crnic L, Segall M. Behavioral effects of mouse interferons-α and -γ and human interferon-α in mice. Brain Res. 1992;590:277-84.
33. 33. Deloria L, Mannering G. Interferon induces sleep and other CNS responses in mice recovering from hexobarbital anesthesia. Neuropharmacology. 1993;32:1433-6.
34. 34. Matthys P, Dijkmans R, Proost P, et al. Severe cachexia in mice inoculated with interferon-γ-producing tumor cells. Int J Cancer. 1991;49:77-82.
35. 35. Lewandowski M, Working P, Osterburg I, Vogel F, Korte R, Green J. Developmental toxicity evaluation of recombinant human interferon-γ (rhIFN-γ) in the cynomolgus monkey. Toxicologist. 1991;14:343.
36. 36. PDR. Product information for Actimmune. Physicians' desk reference: Medical Economics. 1995;1082-3.
37. 37. Kato I, Kimura S, Furuhashi T, Nakayoshi H, Takayama S, Uenishi N. Effects of recombinant murine interferon-γ on pregnant mice and their fetuses. Fundam Appl Toxicol. 1990;14:658-65.
38. 38. Vassiliadis S, Athanassakis I. Type II interferon may he a potential hazardous therapeutic agent during pregnancy. Br J Haematol. 1992;82:782-3.
39. 39. Bass R, Kleeberg U, Schroder H, Scheibner E. Current guidelines for the preclinical safety assessment of therapeutic proteins. Toxicol Lett. 1992:64/65:339-47.
40. 40. Bemiller LS, Roberts DH, Starko KM, Curnutte JT. Safety and efficacy of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Molecules Dis. 1995; 21:239-47.
41. 41. Filler R. Methods for evaluation of rat epididymal sperm morphology. In: Chapin RE, Heindel JJ, eds. Male reproductive toxicology. New York: Academic Press; 1993:334-43.
42. 42. Sokal R, Rohlf F. Bartlett's test of homogeneity of variances. Biometry. San Francisco: W.H. Freeman and Co., 1969:370-89.
43. 43. Snedecor G, Cochran W. Analysis of variance. Statistical methods. Ames: Iowa State University Press; 1967:258-75.
44. 44. Dunnett C. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc. 1955;50:1096-129.
45. 45. Dunn O. Multiple comparisons using rank sums. Technometrics. 1964;6:241-52.
46. 46. Wilson C, Penix L, Weaver W, Melvin A, Lewis D. Ontogeny of T lymphocyte function in the neonate. Am J Reprod Immunol. 1992;28:132-5.
47. 47. Wilson C, Lewis D. Basis and implications of selectively diminished cytokine production in neonatal susceptibility to infection. Rev Infect Dis. 1990;12:S410-S20.
48. 48. Tomai M, Fitzgerald T, Froberg M. Macrophage and lymphocyte functions are downregulated in newborn rabbits, J Leukoc Biol. 1992;51:151-6.
49. 49. Macdonald T. Development of mucosal immune function in man: Potential for GI disease states. Acta Paediatr Jpn. 1994;36:532-6.
50. 50. Hill H. Modulation of host defenses with interferon-γ in pediatrics. J Infect Dis. 1993;167:S23-S8.
51. 51. Taylor S, Bryson Y. Impaired production of γ-interferon by newborn cells in vitro is due to a functionally immature macrophage. J Immunol. 1985;134:1493-7.
52. 52. Wakasugi N, Virelizier J-L. Defective IFN-γ production in the human neonate. I. Dysregulation rather than intrinsic abnormality. J Immunol. 1985;134:167-71.
53. 53. Lewis D, Yu C, Meyer J, English B, Kahn S, Wilson C. Cellular and molecular mechanisms for reduced interleukin-4 and interferon-γ production by neonatal T cells. J Clin Invest. 1991;87:194-202.
54. 54. Lewis D, Larsen A, Wilson C. Reduced interferon-gamma mRNA levels in human neonates: Evidence for an intrinsic T cell deficiency independent of other genes involved in T cell activation. J Exp Med. 1986;163:1018-23.
55. 1 enhances expression of 50 kDa protein related to 2′-5′ oligoadenylate synthetase in human sperm cells. J Cell Physiol. 1991;146:156-63.
56. 56. Haney A, Hughes S, Weinberg J. The lack of effect of tumor necrosis factor-alpha, interleukin-1-alpha, and interferon-gamma on human sperm motility in vitro. J Androl. 1992;13:249-53.
57. 57. Naz R, Mehta K. Cell-mediated immune responses to sperm antigens: Effects on mouse sperm and embryos. Biol Reprod. 1989; 41:533-42.
58. 58. Kalla N, Mann A, Sharma R, Aulitzky W, Frick J. Effects of human gamma interferon on mice testis: A quantitative analysis of the spermatogenic cells. Acta Eur Fertil. 1992;23:89-94.
59. 59. Schreiber R, Farrar M, Hershey G, Fernandez-Luna J. The structure and function of interferon-γ receptors. Int J Immunopharmacol. 1992;14:413-9.
60. 60. Meikle A, de Sousa J, Dacosta N, Bishop D, Samlowski W. Direct and indirect effects of murine interleukin-2, gamma interferon, and tumor necrosis factor on testosterone synthesis in mouse Leydig cells. J Androl. 1992;13:437-43.
61. 61. Tokuda N, Kasahara M, Levy R. Differential regulation and expression of major histocompatibility complex (MHC) and Ly-6 gene products on mouse testicular leydig and sertoli cell lines. J Autoimmun. 1990;3:457-71.
62. 62. Orava M, Cantell K, Vihko R. Human leukocyte interferon inhibits human chorionic gonadotropin stimulated testosterone production by porcine Leydig cells in culture. Biochem Biophys Res Commun. 1985;127:809-15.
63. 63. Orava M, Cantell K, Vihko R, Treatment with preparations of human leukocyte interferon decreases serum testosterone. Int J Cancer. 1986;38:295-6.
64. 64. Soramoto S, Hiramine C, Takenaka I, HoJo K. Murine experimental autoimmune orchitis (EAO) induced by syngeneic testicular germ cells (TC) alone: Orchitogenic and lymphostimulatory activities of TC from mice at various ages. Clin Immunol Immunopathol. 1993;69:292-9.
65. 65. Dudley D, Chen C, Mitchell M, Daynes R, Araneo B. Adaptive immune responses during murine pregnancy: Pregnancy-induced regulation of lymphokine production by activated T lymphocytes. Am J Obstet Gynecol. 1993;168:1155-63.
66. 66. Yu M, Fredrikson S, Link J, Link H. High numbers of autoantigenreactive mononuclear cells expressing interferon-gamma (IFN-γ), IL-4 and transforming growth factor-beta (TGF-β) are present in cord blood. Clin Exp Immunol. 1995;101:190-6.
67. 67. Abbas A, Thilaganathan B, Buggins A, Layton D, Nicolaides K. Fetal plasma interferon gamma concentrations in normal pregnancy. Am J Obstet Gynecol. 1993;168:1414-6.
68. 68. la Bonnardiere C. No detection of Interferon-γ activity during early pregnancy in the mouse. Am J Reprod Immunol. 1993;30:26-31.
69. 69. Chen H, Kamath R, Pace J, Russell S, Hunt J. Gestation-related expression of the interferon-γ receptor gene in mouse uterine and embryonic hematopoietic cells. J Leukoc Biol. 1994;55:617-25.
70. 70. Paulesu L, Romagnoli R, Cintorino M, Ricci M, Garotta G. First trimester human trophoblast expresses both interferon-γ and interferon-γ receptor. J Reprod Immunol. 1994;27:37-48.
71. 71. Kauppila A, Cantell K, Janne O, Kokko E, Vihko R. Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. Int J Cancer. 1982;29:291-4.
72. 72. Athanassakis I, Vassiliadis S. Effect of IFN-γ administration in virgin and pregnant mice: Distribution of lymphoid and myeloid cells in the spleen. Eur Cytokine Netw. 1995;6:167-76.
73. 73. Hill J, Haimovici F, Anderson D. Products of activated lymphocytes and macrophages inhibit mouse embryo development in vitro. J Immunol. 1987;139:2250-4.
74. 74. Chaouat G. Synergy of lipopolysaccharide and inflammatory cytokines in murine pregnancy: Alloimmunization prevents abortion but does not affect the induction of preterm delivery. Cell Immunol. 1994;157:328-40.
75. 75. Hill J, Polgar K, Harlow B, Anderson D. Evidence of embryo-and trophoblast-toxic cellular immune response(s) in women with recurrent spontaneous abortion. Am J Obstet Gynecol. 1992;166: 1044-52.
76. 76. Mattsson R, Mattsson A, Holmdahl R. Scheynius A, Van Der Meide P. In vivo treatment with interferon-gamma during early pregnancy in mice induces strong expression of major histocompatibility complex class I and II molecules in uterus and decidua but not in extra-embryonic tissues. Biol Reprod. 1992;46:1176-86.
77. 77. Mattsson R, Holmdahl R, Scheynius A, Bernadotte F, Mattsson A, Van der Meide P. Placental MHC class I antigen expression is induced in mice following in vivo treatment with recombinant interferon-gamma. J Reprod Immunol. 1991;19:115-29.
78. 78. Weinberger S, Schulteis G, Fernando A, Bakhit C, Martinez JJ. Decreased locomotor activity produced by repeated, but not single, administration of murine-recombinant interferon-gamma in mice. Life Sci. 1988;42:1085-90.